|
|||||
|
|
Tocilizumab as monotherapy or in combination with nonbiologic disease‐modifying antirheumatic drugs: Twenty‐four–week results of an open‐label,clinical practice study |
|
| Authors: | Michael E. Weinblatt Lichen L. Teng Jenny Devenport Natasha Singh Denise Lepley Mark C. Genovese |
| Affiliation: | 1. Brigham and Women's Hospital, Boston, MassachusettsDr. Weinblatt has received consultant fees and/or honoraria (less than $10,000 each) from Amgen, AstraZeneca, Centocor, Merck, and UCB, and (more than $10,000 each) from Abbott, Pfizer, and Roche/Genentech.;2. Roche, Nutley, New Jersey;3. Genentech, South San Francisco, California;4. Stanford University Medical Center, Stanford, California |
| Abstract: | |
| Keywords: | |